Anti-inflammatory Effect of Agaricus Blazei Murill in Inflammatory Bowel Disease (IBD)

University of Oslo (UIO)

Status and phase: Completed; Phase 3; Phase 2

Conditions: Inflammatory Bowel Disease; Ulcerative Colitis; Crohn's Disease

Treatments: Dietary Supplement: Sugar Extract; Dietary Supplement: AndoSan

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT01496053

AbM2012-IBD

Details and patient eligibility

About

Examine whether daily oral ingestion of a immunomodulatory mushroom extract (AndoSanTM) in patients with ulcerative colitis (UC) and Crohn's disease (CD), experience clinical, biochemical and genetical improvement in their disease.

A prospective randomised study comparing the mushroom extract with placebo.

Enrollment: 100 patients

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• moderate disease

Exclusion criteria

• serious disease,
• biological treatment,
• pregnancy.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

100 participants in 2 patient groups

AndoSan

Active Comparator group

Description:

AndoSan given to IBD patients

Treatment:

Dietary Supplement: AndoSan

Sugar extract

Sham Comparator group

Description:

Sugar extract to IBD patients

Treatment:

Dietary Supplement: Sugar Extract